Patrick Hughes

Collaboration and regulation were the watchwords at DIA Global this year, where the ICH E6(R3) guideline, published in final draft form in May, was the talk of the congress.

How it has taken a global pandemic to reinforce the intrinsic benefits.

Roundtable gathers industry experts to discuss the guidance update’s early implementation and the shift toward risk-based study execution approaches.

The industry-wide shift towards RBx is not only reducing risk, but improving oversight and boosting proactive, predictive decision making, writes Cluepoints' CCO, Patrick Hughes.

Small and medium-sized businesses are seeking clarification on how the new ICH E6 guidelines will impact their business.

The release of the ICH E6 R2 guidance, which outlines a new approach to clinical trials operations, will have a major impact on the industry, writes Patrick Hughes.